Adjuvant High-dose-rate Brachytherapy in the Management of Oral Cavity Cancers: 5 Years of Experience in Iran

Overview

Journal J Contemp Brachytherapy

Date 2017 Sep 28

PMID 28951751

Citations 2

Authors

Ali Kazemian

Mohammad Babaei

Marzieh Lashkari

Reza Ghalehtaki

Ata Garajei

Maziar Motiee-Langroudi

Ahmadreza Sebzari

Ramin Jaberi

Soraya Gholami

Somayyeh Babaloui

Mahdi Aghili

Affiliations

Soon will be listed here.

Abstract

Purpose: Brachytherapy is a cost-effective method for the management of oral cavity cancers in low to middle income countries. We aimed to evaluate the clinical outcomes of high-dose-rate interstitial brachytherapy (HDR-IBT) in patients with oral cavity cancer.

Material And Methods: From 2009 to 2013, 78 patients (49 combined external beam radiotherapy [EBRT] plus IBT and 29 IBT monotherapy) with oral cavity cancers had been treated in our center. Slightly more than half the patients were male, and the median age was 54 years. The treatment was planned based on the Paris system. The main outcomes were disease-free and overall survival.

Results: The median follow-up duration was 36.5 months (range, 1.17-54.23). The actuarial four-year overall and disease-free survival rates were 83% and 65%, respectively. The local and locoregional control was achieved among 89.74% and 87.17% of patients, respectively. None of the factors including tumor size, node status, gender, and radiation modality (IBT alone vs. IBT + EBRT) had a significant statistical correlation to the local control rate. All the patients tolerated the planned treatment in the IBT alone group. Late complications included a case of trismus and three cases of catheter insertion site fibrosis.

Conclusions: HDR-IBT as a monotherapy or in combination with EBRT is an appropriate option for the management of oral cavity squamous cell carcinomas, and supports the improvement in treatment outcomes and toxicity profiles in adjuvant settings.

Citing Articles

Efficacy of adjuvant external beam radiotherapy and brachytherapy in squamous cell carcinoma of oral tongue: Long-term outcomes.

Shojaei S, Mousavi A, Rahimzadeh P, Kazemian A, Aghili M, Ghalehtaki R J Contemp Brachytherapy. 2025; 16(6):398-409.

PMID: 39943970 PMC: 11812135. DOI: 10.5114/jcb.2024.146837.

Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.

Mattei P, Chabrillac E, Cabarrou B, Dupret-Bories A, Vergez S, Sarini J Strahlenther Onkol. 2021; 198(2):150-158.

PMID: 34786604 DOI: 10.1007/s00066-021-01870-6.

Brachytherapy during the coronavirus disease 2019 - Lessons from Iran.

Aghili M, Jafari F, Vand Rajabpoor M Brachytherapy. 2020; 19(4):412-414.

PMID: 32410912 PMC: 7221400. DOI: 10.1016/j.brachy.2020.05.003.

References

Krishna Rao S, Mejia G, Roberts-Thomson K, Logan R . Epidemiology of oral cancer in Asia in the past decade--an update (2000-2012). Asian Pac J Cancer Prev. 2013; 14(10):5567-77. DOI: 10.7314/apjcp.2013.14.10.5567. View

Goineau A, Piot B, Malard O, Ferron C, Lisbona A, Cassagnau E . Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue. Brachytherapy. 2014; 14(1):71-6. DOI: 10.1016/j.brachy.2014.09.011. View

Umeda M, Komatsubara H, Nishimatsu N, Yokoo S, Shibuya Y, Komori T . High-dose rate interstitial brachytherapy for stage I-II tongue cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90(5):667-70. DOI: 10.1067/moe.2000.110087. View

Shibuya H, Hoshina M, Takeda M, Matsumoto S, Suzuki S, Okada N . Brachytherapy for stage I & II oral tongue cancer: an analysis of past cases focusing on control and complications. Int J Radiat Oncol Biol Phys. 1993; 26(1):51-8. DOI: 10.1016/0360-3016(93)90172-r. View

Bettendorf O, Piffko J, Bankfalvi A . Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy?. Oral Oncol. 2003; 40(2):110-9. DOI: 10.1016/j.oraloncology.2003.08.010. View

Kruaysawat W, Aekplakorn W, Chapman R . Survival time and prognostic factors of oral cancer in Ubon Ratchathani Cancer Center. J Med Assoc Thai. 2010; 93(3):278-84. View

Nakashima T, Nakamura K, Shiratsuchi H, Yasumatsu R, Toh S, Shioyama Y . [Clinical outcome of partial glossectomy or brachytherapy in early-stage tongue cancer]. Nihon Jibiinkoka Gakkai Kaiho. 2010; 113(5):456-62. DOI: 10.3950/jibiinkoka.113.456. View

Kakimoto N, Inoue T, Inoue T, Murakami S, Furukawa S, Yoshida K . Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol. 2003; 68(2):123-8. DOI: 10.1016/s0167-8140(03)00055-0. View

Hepel J, Syed A, Puthawala A, Sharma A, Frankel P . Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005; 62(5):1444-50. DOI: 10.1016/j.ijrobp.2004.12.078. View

10.

Andisheh-Tadbir A, Mehrabani D, Heydari S . Epidemiology of squamous cell carcinoma of the oral cavity in Iran. J Craniofac Surg. 2008; 19(6):1699-702. DOI: 10.1097/SCS.0b013e31818c04cc. View

11.

Guinot J, Santos M, Tortajada M, Carrascosa M, Estelles E, Vendrell J . Efficacy of high-dose-rate interstitial brachytherapy in patients with oral tongue carcinoma. Brachytherapy. 2010; 9(3):227-34. DOI: 10.1016/j.brachy.2009.10.003. View

12.

Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N . Brachytherapy for early oral tongue cancer: low dose rate to high dose rate. J Radiat Res. 2003; 44(1):37-40. DOI: 10.1269/jrr.44.37. View

13.

Sargeran K, Murtomaa H, Safavi S, Vehkalahti M, Teronen O . Survival after diagnosis of cancer of the oral cavity. Br J Oral Maxillofac Surg. 2007; 46(3):187-191. DOI: 10.1016/j.bjoms.2007.11.004. View

14.

Khalilur R, Hayashi K, Shibuya H . Brachytherapy for tongue cancer in the very elderly is an alternative to external beam radiation. Br J Radiol. 2010; 84(1004):747-9. PMC: 3473442. DOI: 10.1259/bjr/23130739. View

15.

Leung T, Wong V, Wong C, Tung S, Lui C, Leung L . High dose rate brachytherapy for carcinoma of the oral tongue. Int J Radiat Oncol Biol Phys. 1997; 39(5):1113-20. DOI: 10.1016/s0360-3016(97)00376-3. View

16.

Lau H, Hay J, Flores A, Threlfall W . Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol. 1996; 39(1):15-8. DOI: 10.1016/0167-8140(95)01686-4. View

17.

Lee S, Cho K, Moon S, Choi S, Park J, Yun T . Clinical outcome of high-dose-rate interstitial brachytherapy in patients with oral cavity cancer. Radiat Oncol J. 2015; 32(4):238-46. PMC: 4282998. DOI: 10.3857/roj.2014.32.4.238. View

18.

Ameri A, Heydarirad G, Rezaeizadeh H, Choopani R, Ghobadi A, Gachkar L . Evaluation of Efficacy of an Herbal Compound on Dry Mouth in Patients With Head and Neck Cancers: A Randomized Clinical Trial. J Evid Based Complementary Altern Med. 2015; 21(1):30-3. DOI: 10.1177/2156587215590232. View

19.

Petera J, Matula P, Paluska P, Sirak I, Macingova Z, Kasaova L . High dose rate versus low dose rate brachytherapy in the treatment of tongue carcinoma - a radiobiological study. Neoplasma. 2009; 56(2):163-8. DOI: 10.4149/neo_2009_02_163. View

20.

Razmpa E, Memari F, Naghibzadeh B . Epidemiologic and clinicopathologic characteristics of tongue cancer in Iranian patients. Acta Med Iran. 2011; 49(1):44-8. View